Gapping up
In reaction to earnings/guidance:
- SFIX +12.2% (also launches Stitch Fix Freestyle) GIS +2.6% GDEV +1.8% TUYA +1.6% BDSI +1.3% (guides Q3 revs below consensus)
Other news:
- ELMS +6.4% (has received a binding purchase order for 1000 units of its Urban Delivery vehicle from its strategic distribution partner Randy Marion Automotive Group)
- RKLB +4.6% (signs dedicated launch contract with Astroscale Japan)
- BLUE +3.9% (submits BLA to the FDA for beti-cel gene therapy)
- ENLV +3.8% (doses first patient in placebo-controlled Phase IIb Clinical Trial of Allocetra in severe and critical COVID-19 patients with ARDS)
- RYTM +3.7% (receives Marketing Authorization for IMCIVREE in Great Britain)
- ARCT +3.3% (receives approval from Vietnam Ministry of Health to proceed into Phase 2 and Phase 3a for ARCT-154)
- AMAL +2.9% (acquires Amalgamated Bank of Chicago)
- VALE +2.3% (appoints Gustavo Pimenta as Executive Vice President of Finance and Investor Relations)
- SAH +2% (adds $3.2 billion in annualized revenues with acquisition of RFJ Auto Partners)
- EQR +1.6% (provides operating update)
- SWN +1.3% (KMI and SWN announce responsibly sourced natural gas agreement)
- BSN +1.3% (merger partner Vertical Aerospace announces Marubeni Corporation's pre-order option for up to 200 aircraft and signs Mou to explore the introduction of eVTOL aircraft in Japan)
- AMWL +1.2% (names new CFO)
- KMI +1.1% (KMI and SWN announce responsibly sourced natural gas agreement)
- JPM +1% (increases dividend)
Analyst comments:
- CDTX +6.1% (upgraded to Strong Buy from Buy at WBB Securities)
- PMVP +5.5% (upgraded to Buy from Neutral at Goldman)
- TECK +3.9% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- AMBA +3.3% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- PEBO +1.7% (upgraded to Overweight from Neutral at Piper Sandler)
- SPG +1.4% (upgraded to Buy from Hold at Argus)
- ACN +1.1% (upgraded to Buy from Neutral at MoffettNathanson)